Skip to main content
SpringerLink
Log in

Apremilast decreases budget, cost effective for psoriasis

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 British pounds

  2. Canadian dollars

  3. 2016 euros

References

  1. Mughal F, et al. Budget Impact of Apremilast for Moderate to Severe Plaque Psoriasis in the Uk. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSS15, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=46813.

  2. Mughal F, et al. Budget Impact of Apremilast for Active Psoriatic Arthritis in the Uk. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS14, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47942.

  3. Martinez-Sesmero JM, et al. Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSS41, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47264.

  4. Cawston H, et al. Cost-Effectiveness of Apremilast in Moderate-to-Severe Psoriasis in Canada. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY71, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47727.

  5. Morell A, et al. Cost and Cost Per Responder in Spain of Adalimumab, Methotrexate and Apremilast in the Treatment of Methotrexate-Naive Patients with Psoriatic Arthritis. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS56, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47879.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apremilast decreases budget, cost effective for psoriasis. PharmacoEcon Outcomes News 767, 6–7 (2016). https://doi.org/10.1007/s40274-016-3566-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3566-3

Search

Navigation